![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/18/2900339/37704/en/CytomX-Therapeutics-to-Present-at-the-H-C-Wainwright-2nd-Annual-Immune-Cell-Engager-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/06/17/2900015/37704/en/CytomX-Therapeutics-Promotes-Chris-Ogden-to-Chief-Financial-Officer.html
https://www.globenewswire.com/news-release/2024/05/22/2886834/37704/en/CytomX-Therapeutics-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/16/2883880/37704/en/CytomX-Therapeutics-Announces-New-Employment-Inducement-Grants.html
https://endpts.com/cytomxs-amgen-partnered-t-cell-engager-yields-mixed-phase-1-data/
https://www.globenewswire.com/news-release/2024/05/08/2878255/37704/en/CytomX-Therapeutics-Announces-Positive-Initial-Phase-1a-Dose-Escalation-Data-for-Monotherapy-CX-904-EGFRxCD3-PROBODY-T-Cell-Engager.html
https://www.globenewswire.com/news-release/2024/05/08/2878253/37704/en/CytomX-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/07/2877258/37704/en/CytomX-Therapeutics-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-CX-801-in-Combination-with-KEYTRUDA-pembrolizumab.html
https://www.globenewswire.com/news-release/2024/05/01/2873162/37704/en/CytomX-Therapeutics-to-Report-First-Quarter-2024-Results-and-Provide-an-Initial-CX-904-Phase-1a-Clinical-Data-Update-on-May-8-2024.html
https://www.globenewswire.com/news-release/2024/04/08/2859133/37704/en/CytomX-Therapeutics-Announces-First-Patient-Dosed-with-CX-2051-a-Conditionally-Activated-EpCAM-Directed-ADC-in-a-Phase-1-Study-in-Patients-with-Advanced-Solid-Tumors.html